Article Text

Download PDFPDF
Preliminary results of clinical use of colchicine in COVID-19 treatment
  1. Rafael Silvestre Knack1,
  2. Luis Carlos Losso1,2,
  3. Renata Silvestre Knack3 and
  4. Talie Hanada4
  1. 1Hospital Israelita Albert Einstein, Sao Paulo, Brazil
  2. 2Edmundo Vasconcelos Hospital, Sao Paulo, Brazil
  3. 3FAEPE - Fundação de Apoio a Pesquisa e a Extensão de Serviços da Comunidade FAMERP, São José do Rio Preto, São Paulo, Brazil
  4. 4Universidade Metropolitana de Santos, Santos, Brazil
  1. Correspondence to Dr Rafael Silvestre Knack; dr.rafaelknackhiae{at}


We report a case of the use of colchicine in a patient infected with SARS-CoV-2 virus. A 37-year-old man with COVID-19 presented with moderate symptoms, mild pulmonary impairment and elevated inflammatory markers, suggesting an increased risk of cytokine storm and possible worsening of clinical condition. Experimental use of colchicine resulted in an 85% decrease in C reactive protein levels 3 days after treatment initiation and a 182.6% decrease in interleukin-6 levels 8 days after treatment initiation. Due to the lack of effective therapies, it is important to search for potential compounds and compounds that focus on controlling the danger caused by systemic inflammation in COVID-19. Although further research is needed in the area of colchicine and viral infection, preliminary efficacy was observed.

  • COVID-19
  • infectious diseases

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors RSK elaborated the project; LCL elaborated the project; RSK wrote the manuscript; TH revised the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.